A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
NCT01614197
Completed
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/25/2023
Locations: Rainbow Babies, Cleveland, Ohio +1 locations
Conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Register for Updates
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
NCT03328104
Completed
T- cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy) has an increase in proteins in a specific pathway called the mTOR pathway within the cancer cells. In cancer cells it can encourage untimely cell growth, cell production, and cell survival. Everolimus is an inhibitor of the mTOR pathway and can decrease the growth and survival of cancer cells. It also prevents communication within cells and stops proteins from being made that may contribute to leukemia. The mai... Read More
Gender:
ALL
Ages:
Between 2 years and 29 years
Trial Updated:
07/20/2023
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05244070
Terminated
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Local Institution - 0009, Columbus, Ohio
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma
Register for Updates
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
NCT00074165
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substan... Read More
Gender:
ALL
Ages:
Between 18 months and 75 years
Trial Updated:
06/21/2023
Locations: Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio
Conditions: Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Register for Updates
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00828009
Completed
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Mercy Cancer Center at Mercy Medical Center, Canton, Ohio +2 locations
Conditions: Lung Cancer
Register for Updates
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
NCT00014508
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening. PURPOSE: Phase II trial to study the effe... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/20/2023
Locations: Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio +1 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00005962
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURP... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2023
Locations: Ireland Cancer Center, Cleveland, Ohio +3 locations
Conditions: Leukemia
Register for Updates
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
NCT00003910
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of methotrexate with or without cyclophosphamide in treating patients who have lymphocytic leukemia with neutropenia or anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Aultman Cancer Center at Aultman Hospital, Canton, Ohio +1 locations
Conditions: Leukemia
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/15/2023
Locations: Aultman Cancer Center at Aultman Hospital, Canton, Ohio +2 locations
Conditions: Lymphoma
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Aultman Cancer Center at Aultman Hospital, Canton, Ohio +14 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00003389
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/14/2023
Locations: McDowell Cancer Center at Akron General Medical Center, Akron, Ohio +56 locations
Conditions: Lymphoma
Register for Updates
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282
Completed
RATIONALE: Drugs used in chemotherapy, such as pentostatin, cyclophosphamide, and CAMPATH-1H work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well pentostatin, cyclophospha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Case Comprehensive Cancer Center, Cleveland, Ohio +2 locations
Conditions: Leukemia
Register for Updates